Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock
November 13, 2026
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
October 20, 2022
Related Post
-
-
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 13, 2026
-
INOVIO to Participate in Upcoming Investor Conferences
November 11, 2026
-
Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium
November 11, 2026